RetinalGeniX Technologies: Preventing Blindness and Early Detection of Multiple Systemic Diseases
RetinalGeniX Technologies Inc. is making significant strides in the field of ophthalmic research and development. Their focus lies in the prevention of blindness and the early detection of multiple systemic diseases. By combining genetic markers and high-resolution retinal imaging, the company aims to revolutionize disease treatment.
Key Takeaways:
Advancing Disease Treatment through Genetic Markers and Imaging
RetinalGeniX Technologies is at the forefront of developing innovative technologies for disease diagnosis and treatment. By combining high-resolution imaging, pharmacogenetic portal software, and diagnostic testing, the company aims to provide accurate and personalized treatment options.
Webinar Highlights the Future of Disease Prevention
A recent webinar conducted by RetinalGeniX Technologies shed light on the company’s progress and future prospects. The webinar delved into the development of RNA/DNA GPS lab test kits, CLIA lab progress, pending IRB protocol study, and new drug patent development. These advancements could potentially aid in the reassignment of existing drug patents for drug therapeutics.
Patent for Innovative Patient Home Monitoring System
RetinalGeniX Technologies recently received a patent for their Patient Home Monitoring and Integrated Physician Alert System for Ocular Anatomy. This remote monitoring device allows physicians to perform pre-diagnostic evaluations remotely, thereby determining the need for in-person medical diagnosis. The patent highlights the company’s commitment to improving patient care and accessibility to medical services.
Expanding Scope: Early Detection of Systemic Diseases
RetinalGeniX Technologies recognizes the interconnectedness of ocular diseases with neurodegenerative, cardiovascular, vascular, metabolic, and diabetic conditions. The company is actively developing technologies to detect and treat these systemic disorders. Their DNA/RNA/GPS Pharmaco-Genetic Mapping software, accessible through an application, provides vital bio-marker information to aid in drug development.
Revolutionizing Retinal Screening and Monitoring
RetinalGeniX Technologies is dedicated to enhancing retinal screening and monitoring methods. They are working on a high-resolution retinal home monitoring system that offers real-time alerts to both physicians and patients. Additionally, the company is developing a cost-effective high-resolution retinal mass screening device that captures a wide field of view without the need for pupil dilation. These advancements will greatly improve early detection and treatment outcomes.
By presenting this information in a clear and concise manner, RetinalGeniX Technologies is paving the way for a future where blindness and systemic diseases can be effectively prevented and treated.
